Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial. Academic Article uri icon

Overview

abstract

  • NCT02263326.

publication date

  • May 17, 2018

Research

keywords

  • Anti-HIV Agents
  • HIV Infections
  • HIV-1
  • Heterocyclic Compounds, 3-Ring
  • Lamivudine

Identity

PubMed Central ID

  • PMC5961309

Scopus Document Identifier

  • 85047540507

Digital Object Identifier (DOI)

  • 10.1093/cid/cix1131

PubMed ID

  • 29293895

Additional Document Info

volume

  • 66

issue

  • 11